Kopran’s wholly owned subsidiary - Kopran Research Laboratories has been inspected by the United States Food and Drug Administration (USFDA) starting from January 21 till January 25, 20 l 9. The Inspection has been completed without issuance of any observation.
This will facilitate commencement of supplies of APIs to the US market once DMF's are filed and approved. The company has filed the DMF of Atenolol which is already reviewed and active.
Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.
